SCHEMBL5466697

SCHEMBL5466697

NC(=S)CCS(=O)(=O)c1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 4/20 0.58
L3MBTL1 Q9Y468 1/20 0.53
MAPT P10636 1/20 0.50
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA9 Q16790 1/20 0.49
KDM4E B2RXH2 1/20 0.48
PSIP1 O75475 1/20 0.47
RAB9A P51151 4/20 0.46
POLB P06746 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
HTT P42858 1/20 0.46
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC10 Q969S8 1/20 0.46
HDAC11 Q96DB2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1161573 0.82 HSD11B1 (0.65) HSD11B1L3MBTL1MAPTCA12CA1
SCHEMBL5467897 0.80 HSD11B1 (0.53) HSD11B1MAPTCA12CA1CA2
SCHEMBL1001018 0.78 HSD11B1 (0.69) HSD11B1L3MBTL1MAPTCA12CA1
SCHEMBL6803059 0.77 HDAC1 (0.54) HSD11B1L3MBTL1MAPTCA12CA1
SCHEMBL2810870 0.77 HDAC1 (0.58) HSD11B1L3MBTL1MAPTCA12CA1
SCHEMBL777601 0.76 PSIP1 (0.67) HSD11B1L3MBTL1MAPTCA12CA1
Hydrochloric Acid SCHEMBL10584023 0.76 HSD11B1 (0.67) HSD11B1L3MBTL1MAPTCA12CA1
SCHEMBL5214593 0.76 MAPT (0.62) HSD11B1L3MBTL1MAPTKDM4EPSIP1
Hydrochloric Acid SCHEMBL5124026 0.76 HDAC1 (0.57) HSD11B1L3MBTL1MAPTCA12CA1
SCHEMBL11315802 0.76 PSIP1 (0.45) HSD11B1L3MBTL1MAPTCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032518-A1 Compounds and methods of use AMGEN INC. (US) 2007-02-08 US disclosed
EP-1478645-A2 QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS Amgen Inc. (US) 2004-11-24 EP disclosed
US-6822097-B1 THIAZOLE-SUBSTITUTED QUINOLINE DERIVATIVES; ANTICARCINOGENIC AGENTS, ANTISTROKE AGENTS; APOPTOSIS AND CELL PROLIFERATION TREATMENT; NERVOUS SYSTEM DISORDERS AMGEN, INC. 2004-11-23 US disclosed
WO-2003066630-A2 QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS AMGEN INC. (US) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032518-A1 Compounds and methods of use BAX, BAD, CASP3 HSD11B1 750/4885L3MBTL1 1471/4885MAPT 1974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.